stp707
Nucleic acidexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2021 (NCT05037149)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Transforming growth factor beta-1ANTISENSE INHIBITOR
TGFB1 antisense inhibitor
- Cyclooxygenase-2ANTISENSE INHIBITOR
PTGS2 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05309915 | Phase 1 | Feb 28, 2022 | Medpace, Inc., Sirnaomics |
| NCT05037149 | Phase 1 | Nov 1, 2021 | Sirnaomics |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sirnaomics | For profit | 2 | 2 | 1 | 2021 |
| Medpace, Inc. | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1